Clinical potential of gene mutations in lung cancer
AbstractLung cancer is the most common cancer type worldwide and the leading cause of cancer related deaths in the United States. The majority of newly diagnosed patients present with late stage metastatic lung cancer that is inoperable and resistant to therapies. High‐throughput genomic technologie...
Main Authors: | Miranda B. Carper, Pier Paolo Claudio |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-12-01
|
Series: | Clinical and Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40169-015-0074-1 |
Similar Items
-
An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer
by: Tamkin Ahmadzada, et al.
Published: (2018-06-01) -
Frequency and clinical relevance of EGFR mutations and EML4–ALK translocations in octogenarians with non-small cell lung cancer
by: Tufman A, et al.
Published: (2017-10-01) -
EGFR Mutations in Surgically Resected Fresh Specimens from 697 Consecutive Chinese Patients with Non-Small Cell Lung Cancer and Their Relationships with Clinical Features
by: Yuanyang Lai, et al.
Published: (2013-12-01) -
EGFR mutated lung cancer: current therapies and potential future treatments
by: Polio, Andrew
Published: (2016) -
The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
by: Ramon Andrade De Mello, et al.
Published: (2020-06-01)